iPharmag is an independent online publication covering the pharmaceutical and biotechnology industry: drug approvals and pipelines, clinical research, regulatory decisions, company results, manufacturing, and the medical science behind new therapies. Our goal is simple — to make important developments in medicine clear and accessible to professionals, investors, patients, and curious readers alike.
What we cover
We follow the news that shapes how medicines are discovered, approved, made, and used — including regulatory agencies (FDA, EMA and others), major and emerging drug developers, clinical-trial results, and the business of biopharma. Where a story touches patient care, we report it as information, never as medical advice.
How we produce our articles
Every article is written from reputable, publicly available sources — company announcements, regulatory filings, peer-reviewed research, and established news outlets. We do not copy those sources. Each story is synthesized and rewritten in our own words, with the original sources listed and linked on the page so you can always read the primary material yourself.
For a full account of our sourcing, accuracy, corrections and AI-disclosure practices, see our Editorial Standards.
Editorial independence
Our reporting is independent. Advertising and our paid research products help fund the site, but they do not influence which stories we cover or how we cover them.
Get in touch
Questions, tips, or corrections are welcome — see our Contact page. Legal and publisher details are in our Impressum.
The information on iPharmag is provided for general knowledge and is not medical advice. Always consult a qualified healthcare professional for decisions about your health or treatment.